Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PHAT Stock Forecast 2025-2026
$4.11
Current Price
$286.95M
Market Cap
Buy 8
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to PHAT Price Targets
+581.3%
To High Target of $28.00
+410.9%
To Median Target of $21.00
+143.3%
To Low Target of $10.00
PHAT Price Momentum
+5.4%
1 Week Change
-37.7%
1 Month Change
-55.2%
1 Year Change
-49.4%
Year-to-Date Change
-79.1%
From 52W High of $19.71
+7.9%
From 52W Low of $3.81
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Phathom (PHAT) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PHAT and similar high-potential opportunities.
Latest PHAT Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, PHAT has a bullish consensus with a median price target of $21.00 (ranging from $10.00 to $28.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $4.11, the median forecast implies a 410.9% upside. This outlook is supported by 8 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joseph Stringer at Needham, projecting a 581.3% upside. Conversely, the most conservative target is provided by Paul Choi at Goldman Sachs, suggesting a 143.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PHAT Analyst Ratings
8
Buy
1
Hold
0
Sell
PHAT Price Target Range
Low
$10.00
Average
$21.00
High
$28.00
Current: $4.11
Latest PHAT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PHAT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 21, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $28.00 |
| Apr 17, 2025 | Goldman Sachs | Paul Choi | Neutral | Maintains | $10.00 |
| Apr 9, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $28.00 |
| Apr 2, 2025 | Guggenheim | Yatin Suneja | Buy | Reiterates | $0.00 |
| Apr 2, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $28.00 |
| Mar 10, 2025 | Goldman Sachs | Paul Choi | Neutral | Maintains | $12.00 |
| Mar 7, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $28.00 |
| Mar 6, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $28.00 |
| Jan 10, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $28.00 |
| Dec 12, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $28.00 |
| Dec 11, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $28.00 |
| Sep 13, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $26.00 |
| Sep 6, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $26.00 |
| Aug 30, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $26.00 |
| Aug 23, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $26.00 |
| Aug 19, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $26.00 |
| Aug 12, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $28.00 |
| Aug 12, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $26.00 |
| Aug 9, 2024 | Goldman Sachs | Paul Choi | Neutral | Maintains | $12.00 |
| Jul 26, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $26.00 |
Phathom Pharmaceuticals Inc. (PHAT) Competitors
The following stocks are similar to Phathom based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Phathom Pharmaceuticals Inc. (PHAT) Financial Data
Phathom Pharmaceuticals Inc. has a market capitalization of $286.95M with a P/E ratio of 0.0x. The company generates $55.25M in trailing twelve-month revenue with a 85.6% profit margin.
Revenue growth is +4,249.6% quarter-over-quarter, while maintaining an operating margin of -200.3% and return on equity of +131.8%.
Valuation Metrics
Market Cap
$286.95M
Enterprise Value
$543.89M
P/E Ratio
0.0x
PEG Ratio
-1.0x
Price/Sales
5.2x
Growth & Margins
Revenue Growth (YoY)
+4,249.6%
Gross Margin
+87.1%
Operating Margin
-200.3%
Net Margin
+85.6%
EPS Growth
+4,249.6%
Financial Health
Cash/Price Ratio
+103.9%
Current Ratio
4.2x
Debt/Equity
-2.2x
ROE
+131.8%
ROA
-43.8%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Phathom Pharmaceuticals Inc. (PHAT) Business Model
About Phathom Pharmaceuticals Inc.
What They Do
Develops treatments for gastrointestinal diseases.
Business Model
The company focuses on developing and commercializing novel treatments for gastrointestinal diseases, primarily through innovative research and drug development. It aims to address conditions such as gastroesophageal reflux disease (GERD) and peptic ulcer disease, generating revenue through potential future drug sales and partnerships.
Additional Information
Phathom Pharmaceuticals is a clinical-stage biopharmaceutical company that is actively working on its pipeline of lead candidates targeting acid-related disorders. Its advancements are significant for stakeholders in the biopharmaceutical sector and have implications for improving patient outcomes and contributing to the broader pharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
427
CEO
Mr. Steven L. Basta M.B.A.
Country
United States
IPO Year
N/A
Website
www.phathompharma.comPhathom Pharmaceuticals Inc. (PHAT) Latest News & Analysis
Latest News
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting
14 hours ago
Quick Summary
Phathom Pharmaceuticals will present real-world data for its FDA-approved treatment VOQUEZNA® at Digestive Disease Week® from May 3-6, 2025, in San Diego.
Why It Matters
Phathom Pharmaceuticals' presentation of real-world data for VOQUEZNA at DDW may boost investor confidence, indicating strong market potential and efficacy of its first-in-class GI treatment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Phathom Pharmaceuticals will host a conference call on May 1, 2025, at 8:00 am EDT to discuss Q1 2025 financial results and provide a business update.
Why It Matters
The conference call on May 1, 2025, will reveal Phathom Pharmaceuticals' Q1 financial results and business updates, crucial for assessing the company's performance and future prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Frazier Life Sciences has appointed Aditya Kohli, Ph.D., as Partner. Since 2016, he has co-founded six life sciences companies, including HilleVax (NASDAQ: HLVX) and Phathom Pharmaceuticals (NASDAQ: PHAT).
Why It Matters
Dr. Kohli's promotion at FLS signals a strong focus on innovative therapeutics, potentially enhancing FLS's portfolio and driving future investment returns in life sciences.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Phathom Pharmaceuticals appointed Ted Schroeder to its Board of Directors, enhancing its leadership as it focuses on gastrointestinal disease treatments.
Why It Matters
The appointment of Ted Schroeder could signal potential strategic shifts or enhanced leadership, impacting Phathom Pharmaceuticals' growth prospects and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
25 days ago
Quick Summary
Phathom Pharmaceuticals will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025, at 10:15 am ET.
Why It Matters
Management participation in the Needham Virtual Healthcare Conference could signal potential updates on product development and strategic direction, influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Thompson shares his experience with GERD and VOQUEZNA, the first FDA-approved PCAB treatment for GERD, as part of the GERD IS NO JOKE campaign.
Why It Matters
Thompson's endorsement of VOQUEZNA highlights its uniqueness as the first FDA-approved PCAB for GERD, potentially boosting sales and market interest for the pharmaceutical company involved.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PHAT Stock
What is Phathom Pharmaceuticals Inc.'s (PHAT) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, Phathom Pharmaceuticals Inc. (PHAT) has a median price target of $21.00. The highest price target is $28.00 and the lowest is $10.00.
Is PHAT stock a good investment in 2025?
According to current analyst ratings, PHAT has 8 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.11. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PHAT stock?
Wall Street analysts predict PHAT stock could reach $21.00 in the next 12 months. This represents a 410.9% increase from the current price of $4.11. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Phathom Pharmaceuticals Inc.'s business model?
The company focuses on developing and commercializing novel treatments for gastrointestinal diseases, primarily through innovative research and drug development. It aims to address conditions such as gastroesophageal reflux disease (GERD) and peptic ulcer disease, generating revenue through potential future drug sales and partnerships.
What is the highest forecasted price for PHAT Phathom Pharmaceuticals Inc.?
The highest price target for PHAT is $28.00 from Joseph Stringer at Needham, which represents a 581.3% increase from the current price of $4.11.
What is the lowest forecasted price for PHAT Phathom Pharmaceuticals Inc.?
The lowest price target for PHAT is $10.00 from Paul Choi at Goldman Sachs, which represents a 143.3% increase from the current price of $4.11.
What is the overall PHAT consensus from analysts for Phathom Pharmaceuticals Inc.?
The overall analyst consensus for PHAT is bullish. Out of 10 Wall Street analysts, 8 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $21.00.
How accurate are PHAT stock price projections?
Stock price projections, including those for Phathom Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 10:28 PM UTC